This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The prevalentce of diagnosed type 2 diabetes mellitus (DM) is currently increasing and is expected to affects 5.4% of adults by the year 2025. Affected individuals have a high risk of blindness, renal failure, amputations, myocardial infarction, stroke and other problems. DM increases the risk of cardiovascular disease (CV) 2-3 fold in men and 3-4 fold in women. Recent observations suggest that even pre-diabetic glucose levels increase CV risk. This highlights the potential health and economic benefits of both preventing DM and reducing CV risk by lowering glucose levels in people wih impaired glucose tolerance (IGT) and other 'pre-diabetic' states. To date there has been no effective and widely applicable method of preventing DM.Progressive high plasma glucose levels in the non-DM range predict an increased DM risk. A recent meta-analysis of 6 longitudinal studies reported that 5% of middle-aged individuals wih IGT develop diabetes annually. For IGT individuals who also had an elevated fasting plasma glucose the rate was approximately 5.8%/year. As IGT is the best studied risk factor for DM that predicts a consistency high incidence across different populations, it will be used as the eligibility criteria for this trial.Ramipril has direct effects o nthe renin-angiotensin-kellikrein system. It may prevent diabetes through effects on the beta cell and by vascular and metabolic effects on muscle (partially mediated by nitric oxide) that may amplify the effects on insulin. Ramipril's effects on insulin sensitivity appear to be indirect. Rosiglitazone's effect appears to be mediated directly through improved insulin improved insulin sensitivity and a possible beta cell cytoprotective effect; it does not appear to directly affect the renin-angiotensin-kallikrein system.The DREAM trial is a large, international, multi-center, randomized, double-blind, placebo controlled trial. A total of at least 4000 participants with IGT will be recruited from major international centers over an 18 month period. They will be randomly allocated to either ramipril and / or rosiglitazone using a 2x2 factoral design and followed for at least 3 years after randomization. Participants will be assessed at regular intervals to ascertain the occurence of the primary outcome (new onset diabetes or all cause mortality) and other secondary outcomes. A diagnosis of diabetes will be made if 2 consecutive plasma glucose levels exceed the diagnostic threholds (i.e. a fasting plasma glucose>=7.0mml/l(126mg/dl) or a 2 hr plasma glucose>=11.1mmol/l (200mg/dl) within a 3 month period.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-CR-4 (02))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Arslanian, Silva; El Ghormli, Laure; Kim, Joon Young et al. (2018) The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in ?-Cell Function in TODAY. Diabetes Care :
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Bertozzi, Beatrice; Tosti, Valeria; Fontana, Luigi (2017) Beyond Calories: An Integrated Approach to Promote Health, Longevity, and Well-Being. Gerontology 63:13-19
Arslanian, Silva; El Ghormli, Laure; Bacha, Fida et al. (2017) Adiponectin, Insulin Sensitivity, ?-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY. Diabetes Care 40:85-93
Obermeit, Lisa C; Beltran, Jessica; Casaletto, Kaitlin B et al. (2017) Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining ""symptomatic"" versus ""asymptomatic"" HAND. J Neurovirol 23:67-78

Showing the most recent 10 out of 497 publications